ArticleJournal of the American Heart Association2026
Prior Antiplatelet Exposure and Clinical Outcomes Among Korean Patients With Acute Myocardial Infarction.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe impact of prior antiplatelet exposure on outcomes of acute myocardial infarction remains unclear, particularly in East Asian populations with distinct antithrombotic response profiles.
methodsThis retrospective cohort study analyzed 29 281 patients with acute myocardial infarction from 2 nationwide Korean registries. After excluding patients with atrial fibrillation, prior coronary artery disease, heart failure, cerebrovascular accident, or thrombolysis and those discharged on oral anticoagulants, 21 304 patients were categorized into previous-user and nonuser groups. Propensity score matching was performed to adjust for baseline differences. The primary outcome was 3-year major adverse cardiac and cerebrovascular events.
resultsPrevious users were older and had more comorbidities and angiographic complexity. Unadjusted analysis showed higher major adverse cardiac and cerebrovascular event rates in previous users, but the difference attenuated after propensity score matching in both the overall matched (adjusted hazard ratio [HR], 0.967 [95% CI, 0.850-1.100]) and selected population (adjusted HR, 1.036 [95% CI, 0.847-1.267]). All-cause death remained slightly elevated in the overall matched cohort (HR, 1.204 [95% CI, 1.004-1.443]) but not in the selected population. In-hospital outcomes and platelet reactivity findings supported the high-risk profile of prior users.
conclusionsPrior antiplatelet exposure was associated with a higher-risk clinical phenotype among patients with acute myocardial infarction, but this relationship was not independent after adjustment for baseline differences. These findings should be interpreted as hypothesis generating and underscore the importance of individualized antithrombotic strategies tailored to risk profiles, particularly in East Asian populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.